Susquehanna International Group, LLP Amgen Inc Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$309.38 - $337.38 $84.1 Million - $91.7 Million	-271,900 Reduced 15.85%	1,443,600 $465 Million
Q2 2024 Aug 15, 2024	SELL	$262.75 - $319.31 $2.79 Million - $3.38 Million	-10,600 Reduced 0.61%	1,715,500 $536 Million
Q1 2024 May 07, 2024	BUY	$268.87 - $324.56 $126 Million - $153 Million	469,900 Added 37.41%	1,726,100 $491 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $85.4 Million - $96.4 Million	-334,100 Reduced 21.01%	1,256,200 $362 Million
Q3 2023 Nov 14, 2023	BUY	$218.65 - $271.46 $50 Million - $62.1 Million	228,700 Added 16.8%	1,590,300 $427 Million
Q2 2023 Aug 11, 2023	SELL	$214.27 - $253.37 $48.3 Million - $57.1 Million	-225,300 Reduced 14.2%	1,361,600 $302 Million
Q1 2023 May 16, 2023	BUY	$225.79 - $275.2 $43.3 Million - $52.8 Million	191,800 Added 13.75%	1,586,900 $384 Million
Q4 2022 Feb 14, 2023	BUY	$229.03 - $291.01 $30.9 Million - $39.3 Million	135,000 Added 10.71%	1,395,100 $366 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $56.9 Million - $64.2 Million	-253,700 Reduced 16.76%	1,260,100 $284 Million
Q2 2022 Aug 15, 2022	BUY	$230.71 - $256.74 $20.7 Million - $23.1 Million	89,800 Added 6.31%	1,513,800 $368 Million
Q1 2022 May 16, 2022	SELL	$219.27 - $242.57 $94 Million - $104 Million	-428,900 Reduced 23.15%	1,424,000 $344 Million
Q4 2021 Feb 14, 2022	BUY	$198.88 - $227.6 $57.5 Million - $65.8 Million	288,900 Added 18.47%	1,852,900 $417 Million
Q3 2021 Nov 15, 2021	SELL	$212.27 - $248.7 $105 Million - $123 Million	-492,900 Reduced 23.96%	1,564,000 $333 Million
Q2 2021 Aug 11, 2021	BUY	$233.58 - $259.14 $64.1 Million - $71.2 Million	274,600 Added 15.41%	2,056,900 $501 Million
Q1 2021 May 17, 2021	BUY	$221.91 - $258.6 $114 Million - $133 Million	512,900 Added 40.4%	1,782,300 $443 Million
Q4 2020 Feb 16, 2021	SELL	$216.38 - $257.67 $31.7 Million - $37.8 Million	-146,600 Reduced 10.35%	1,269,400 $292 Million
Q3 2020 Nov 16, 2020	SELL	$234.65 - $260.95 $19 Million - $21.2 Million	-81,100 Reduced 5.42%	1,416,000 $360 Million
Q2 2020 Aug 14, 2020	SELL	$197.81 - $242.74 $67.8 Million - $83.2 Million	-342,900 Reduced 18.64%	1,497,100 $353 Million
Q1 2020 May 15, 2020	BUY	$182.24 - $241.7 $61.1 Million - $81 Million	335,000 Added 22.26%	1,840,000 $373 Million
Q4 2019 Feb 14, 2020	BUY	$189.21 - $243.2 $47.1 Million - $60.5 Million	248,900 Added 19.82%	1,505,000 $363 Million
Q3 2019 Nov 14, 2019	SELL	$174.11 - $208.62 $47.2 Million - $56.6 Million	-271,100 Reduced 17.75%	1,256,100 $243 Million
Q2 2019 Aug 14, 2019	SELL	$166.7 - $195.41 $72.2 Million - $84.7 Million	-433,300 Reduced 22.1%	1,527,200 $281 Million
Q1 2019 May 15, 2019	BUY	$180.87 - $203.88 $142 Million - $160 Million	783,900 Added 66.62%	1,960,500 $372 Million
Q4 2018 Feb 14, 2019	SELL	$178.4 - $208.25 $28.4 Million - $33.2 Million	-159,400 Reduced 11.93%	1,176,600 $229 Million
Q3 2018 Nov 14, 2018	BUY	$185.29 - $208.89 $11.8 Million - $13.3 Million	63,900 Added 5.02%	1,336,000 $277 Million
Q2 2018 Aug 14, 2018	SELL	$166.05 - $186.51 $66.3 Million - $74.5 Million	-399,200 Reduced 23.89%	1,272,100 $235 Million
Q1 2018 May 15, 2018	BUY	$169.43 - $198.0 $56.8 Million - $66.4 Million	335,300 Added 25.1%	1,671,300 $285 Million
Q4 2017 Feb 14, 2018	SELL	$168.79 - $188.59 $19.5 Million - $21.8 Million	-115,400 Reduced 7.95%	1,336,000 $232 Million
Q3 2017 Nov 20, 2017	BUY	$167.29 - $191.0 $243 Million - $277 Million	1,451,400	1,451,400 $271 Million

Others Institutions Holding AMGN

# of Institutions

3,119

Shares Held

407M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $140B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account